Novocure Reports Second Quarter 2026 Financial Results
Novocure, a global oncology company, reported record net revenues and active patients on therapy for the second quarter of 2026, highlighting the success of its innovative therapy, Tumor Treating Fields (TTFields). CEO Frank Leonard emphasized that this quarter was their strongest yet.
BAAR, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “This was our strongest quarter to date, with record net revenues and active patients on therapy,” said Frank Leonard, CEO, Novocure. “We continue to lau